LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
Category: #health  By Mateen Dalal  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition

LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acquired Everest Biotech, a certified expert in antigen polyclonal antibodies. The acquisition  will help LifeSpan BioSciences expand its product offering and strengthen its position as the fastest growing provider in the market for research reagent.

LSBio, though this partnership, will offer a comprehensive reagents catalogue which can be combined with the wide range of IHC validated primary antibodies.

Heather Holemon, LSBio’s CEO said that the company is looking forward to adding the product range produced by Everest Biotech to its portfolio. The offerings by Everest Biotech stand out owing to their exceptional high quality, which will perfectly complement LSBio’s existing portfolio.

Citing reliable sources, Everest Biotech is committed towards continuous improvement and quality that has ensured the growth of the company’s catalogue. It now has scores of goat antibodies against a wide range of mouse, rat and human targets in the biomedical space.

LSBio’s offering of more than 500,000 polyclonal and monoclonal primary antibodies will expand to include all protein in the proteome after the acquisition. Over 15,000 antibodies of LSBio have been identified as IHC reagents that are exceptional and have been given the IHC-plus brand through the extensive in-house testing.

Apparently, after LSBio acquired Nordic-MUbio in February, the Everest Bio acquisition will mark the second investment made by the company this year.

For the uninitiated, LifeSpan BioSciences, Inc. provides IHC validated reagent antibodies along with services to the global community of pharmaceutical, biotech and academic researchers and has been a leader in the industry after its inception in 1995.

The company has built a catalogue that contains over 750,000 antibodies, proteins, biochemicals and assay kits which it sells through the network of its international distributors.

 

Source Credit-https://finance.yahoo.com/news/lifespan-biosciences-announces-acquisition-everest-080000460.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...